A recent study of 2507 menopausal women suggests that menopausal women with higher caffeine intake are more likely to have hot flashes and night sweats; however, they have fewer problems with mood, memory, and concentration. [...]
About 75% of peri- and postmenopausal women have vasomotor symptoms, such as hot flashes and night sweats; however, some women experience more distress or "bother" in response to these symptoms. A new research study suggests that certain personality traits may affect how women experience these uncomfortable symptoms.
Women with histories of major depression are vulnerable during the transition to menopause and are at increased risk for relapse; however, we have less information on how this transition affects women with bipolar disorder.
A recent meta-analysis concludes that acupuncture is effective for the management of menopausal vasomotor symptoms.
About 70% of perimenopausal women experience vasomotor symptoms, including hot flashes. A new study indicates that a behavioral program focusing on weight loss may help to reduce the severity and frequency of hot flashes.
Various selective serotonin reuptake inhibitors (SSRIs), including citalopram (Celexa), escitalopram (Lexapro) and paroxetine (Paxil), have been shown to be effective for the treatment of menopausal vasomotor symptoms (VMS). Other studies have supported the efficacy of the serotonin–norepinephrine reuptake inhibitors (SNRIs) duloxetine (Cymbalta) and venlafaxine (Effexor). The FDA recently approved a 7.5-mg formulation of paroxetine (marketed as Brisdelle) as the first non-hormonal treatment of hot flashes.
Many women transitioning into the menopause request medical advice on ways to improve their quality of life and to relieve the symptoms associated with the menopausal transition. With concerns regarding the long-term use of estrogen replacement therapy, there has been interest in the use of non-hormonal strategies to manage these symptoms.
A study to be published in an upcoming issue of Menopause suggests that stellate ganglion blockade (SGB) may be an effective option for women with vasomotor symptoms (VMS), including hot flashes and night sweats. SGB is used primarily for pain management and involves the injection of local anesthetic into the stellate ganglion, part of the sympathetic nerve system located in the neck.
Following the publication of the Women's Health Initiative report in 2002, there was a dramatic drop in the use of hormone-replacement therapy (HRT) due to concerns about increased risk of heart disease, breast cancer, and stroke. Since that time, various non-hormonal alternatives have been utilized for the treatment of menopausal symptoms, including gabapentin and various serotonin reuptake inhibitors.
Previous studies have shown that the abrupt hormonal changes that occur after a surgical menopause (i.e., removal of the ovaries) negatively affect cognition in women. According to a recent study, "Women who were younger at the time of surgical menopause have a more rapid rate (steeper slope) of cognitive decline than women who were older at the time of surgery or than women undergoing natural menopause." Earlier age at menopause was also associated with increased Alzheimer’s disease neuropathology, in particular neuritic plaques.
